We next conducted 6-color (hematoxylin, CD40, CD80, CD11c, CD8 and SOX10) multiplex IHC staining on the section of tumors from melanoma patients treated with BRAF inhibitor (Fig. 6 d). This evidence concerns the gene ITGAX and melanoma.